

# Sun Young Rha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598679/publications.pdf>

Version: 2024-02-01

395  
papers

14,797  
citations

31902

53  
h-index

28224

105  
g-index

400  
all docs

400  
docs citations

400  
times ranked

20702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
2	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618.	2.7	3
3	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
4	Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 351-351.	0.8	0
5	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 330-330.	0.8	1
6	First data for sotorasib in patients with pancreatic cancer with <i>KRAS</i> p.G12C mutation: A phase I/II study evaluating efficacy and safety. <i>Journal of Clinical Oncology</i> , 2022, 40, 360490-360490.	0.8	34
7	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. <i>European Urology</i> , 2022, 82, 283-292.	0.9	14
8	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022, 82, P2-13-07-P2-13-07.	0.4	12
9	Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients. <i>European Journal of Oncology Nursing</i> , 2022, 58, 102120.	0.9	6
10	Early Tumor Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	7.7	52
11	Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study. <i>European Journal of Oncology Nursing</i> , 2022, 58, 102138.	0.9	3
12	Phase II Clinical Trial of Eribulin Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3225-3234.	3.2	5
13	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. <i>Future Oncology</i> , 2022, 18, 2623-2634.	1.1	2
14	Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 107-107.	0.8	6
15	Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4164-TPS4164.	0.8	10
16	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4001-4001.	0.8	5
17	Abstract 5445: New discovery and development of transglutaminase 2 inhibitor. <i>Cancer Research</i> , 2022, 82, 5445-5445.	0.4	0
18	Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma. <i>Cancer Research</i> , 2022, 82, CT122-CT122.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14557-e14557.	0.8	0
20	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut</i> , 2021, 70, 829-837.	6.1	94
21	Stable Symptom Clusters and Evolving Symptom Networks in Relation to Chemotherapy Cycles. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 544-554.	0.6	40
22	p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , 2021, 183, 114320.	2.0	11
23	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. <i>Gastric Cancer</i> , 2021, 24, 589-601.	2.7	12
24	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 49-60.	1.3	16
25	Development and validation of a targeted sequencing panel for application to treatment-refractory solid tumor.. <i>Journal of Clinical Oncology</i> , 2021, 39, 245-245.	0.8	4
26	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110428.	1.4	6
27	âœ3Gâœ•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.4	9
28	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
29	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 323-329.	1.3	16
30	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11516-11516.	0.8	1
31	Multi-omics characterization of left-right colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3542-3542.	0.8	0
32	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021, 10, 3249-3260.	1.3	10
33	Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16578-e16578.	0.8	1
34	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4056-4056.	0.8	1
35	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4063-4063.	0.8	1
36	Abstract 945: Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
37	Abstract 2055: Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer. , 2021, , .		0
38	Abstract 2973: Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy. , 2021, , .		0
39	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 2021, 39, 2903-2913.	0.8	154
40	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Oncologist, 2021, 26, e1704-e1729.	1.9	14
41	Prognostic significance of Tâ€cellâ€™inflamed gene expression profile and PDâ€L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	1.3	6
42	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. Cellular Oncology (Dordrecht), 2021, 44, 1387-1403.	2.1	3
43	Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your Life (SMILE)â€™a randomized controlled trial. Supportive Care in Cancer, 2020, 28, 713-723.	1.0	8
44	Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients. Supportive Care in Cancer, 2020, 28, 1419-1431.	1.0	19
45	Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma. Diagnostics, 2020, 10, 750.	1.3	6
46	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy - Oncolytics, 2020, 18, 587-601.	2.0	38
47	Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. Frontiers in Oncology, 2020, 10, 562284.	1.3	1
48	Cross-species chromatin interactions drive transcriptional rewiring in Epsteinâ€™Barr virusâ€™positive gastric adenocarcinoma. Nature Genetics, 2020, 52, 919-930.	9.4	65
49	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 2418-2426.	0.8	55
50	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. Frontiers in Pharmacology, 2020, 11, 608774.	1.6	7
51	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, Tj ETQq1 1 0.784314 rgBT/Overlook Oncology, 2020, 38, 3081-3081.	0.8	24
52	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3590-3590.	0.8	12
53	First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 4534-4534.	0.8	10
54	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF-â€2) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e16505-e16505.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 587.	0.9	9
56	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3054-3054.	0.8	1
57	Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4551-4551.	0.8	0
58	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3520-3520.	0.8	1
59	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. <i>Genomics and Informatics</i> , 2020, 18, e37.	0.4	3
60	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	2.7	16
61	Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 1687-1695.	1.0	20
62	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 143-149.	0.3	7
63	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
64	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
65	EORTC-1203-GITCG - the a€œINNOVATIONa€œ-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. <i>BMC Cancer</i> , 2019, 19, 494.	1.1	86
66	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1153-1163.	2.7	19
67	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 1-11.	1.3	17
68	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	1.3	2
69	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1206-1214.	2.7	28
70	Avelumab (anti-“PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
71	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1108-e1114.	1.9	15
72	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	2.6	31

#	ARTICLE	IF	CITATIONS
73	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
74	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , 2019, 96, 59-69.	0.9	14
75	Prospective validation of a serum miRNA panel for early detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4065-4065.	0.8	1
76	Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using <sup>18</sup> F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. <i>Yonsei Medical Journal</i> , 2019, 60, 604.	0.9	12
77	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
78	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	1.3	10
79	Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 1380-1391.	1.3	20
80	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 851-860.	1.3	14
81	T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 26-26.	0.8	3
82	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1578-1588.	1.3	5
83	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. <i>Gastric Cancer</i> , 2018, 21, 802-810.	2.7	7
84	Rab25 augments cancer cell invasiveness through a $\beta$ 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. <i>Experimental and Molecular Medicine</i> , 2018, 50, e435-e435.	3.2	45
85	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018, 21, 819-830.	2.7	24
86	Forty-nine gastric cancer cell lines with integrative genomic profiling for development of a MET inhibitor. <i>International Journal of Cancer</i> , 2018, 143, 151-159.	2.3	24
87	Screening audit as a quality assurance tool in good clinical practice compliant research environments. <i>BMC Medical Ethics</i> , 2018, 19, 30.	1.0	2
88	The prognostic value of volume-based parameters using <sup>18</sup> F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224.	2.7	32
89	The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. <i>Cancer Nursing</i> , 2018, 41, E49-E57.	0.7	0
90	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1116.	1.1	51

#	ARTICLE	IF	CITATIONS
91	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6171-6180.	0.5	15
92	Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. <i>Cancers</i> , 2018, 10, 455.	1.7	19
93	Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5899-5908.	1.6	6
94	Reconsideration of sample size and power calculation for overall survival in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 90-91.	0.5	2
95	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	1.8	17
96	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
97	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 588.	0.9	24
98	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , 2018, 20, 72.	2.2	0
99	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , 2018, 25, 3222-3230.	0.7	69
100	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	3.2	20
101	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.	6.9	32
102	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018, 18, 158.	1.1	16
103	A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4510-4510.	0.8	8
104	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	0.8	15
105	A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg) Tj ETQq1 1 0.784314 rgBT /Oncology, 2018, 36, TPS707-TPS707.	0.8	2
106	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 383-390.	0.7	9
107	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018, 50, 488-494.	1.3	28
108	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018, 50, 1378-1387.	1.3	12

#	ARTICLE	IF	CITATIONS
109	A Prediction Model of Tumor Progression and Survival in HER2 Positive Metastatic Gastric Cancer Patients treated with Trastuzumab and Chemotherapy. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY31-2.	0.0	0
110	Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL).. Journal of Clinical Oncology, 2018, 36, e16018-e16018.	0.8	0
111	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. Annals of Surgery, 2017, 265, 946-953.	2.1	117
112	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Biochemical Pharmacology, 2017, 123, 73-84.	2.0	3
113	Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. Supportive Care in Cancer, 2017, 25, 1519-1527.	1.0	43
114	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Apmis, 2017, 125, 223-229.	0.9	15
115	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. Investigational New Drugs, 2017, 35, 773-781.	1.2	4
116	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Biochemical Pharmacology, 2017, 138, 163-173.	2.0	9
117	Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.	1.3	37
118	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48
119	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1637-1651.	5.1	233
120	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Oncology Letters, 2017, 14, 2385-2392.	0.8	6
121	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 5981-5992.	3.2	107
122	Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer, 2017, 17, 283.	1.1	93
123	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget, 2017, 8, 61837-61845.	0.8	16
124	A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, 294-294.	0.8	3
125	Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial.. Journal of Clinical Oncology, 2017, 35, 48-48.	0.8	4
126	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 2017, 8, 31169-31179.	0.8	13



#	ARTICLE	IF	CITATIONS
127	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 38389-38398.	0.8	8
128	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	0.8	34
129	PD-L1 expression in patients with metastatic gastric cancer in South Korea.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1571-1571.	0.8	1
130	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. <i>American Journal of Cancer Research</i> , 2017, 7, 134-138.	1.4	6
131	Rho GTPase Rhoj is Associated with Gastric Cancer Progression and Metastasis. <i>Journal of Cancer</i> , 2016, 7, 1550-1556.	1.2	16
132	Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. <i>Yonsei Medical Journal</i> , 2016, 57, 831.	0.9	12
133	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016, 7, 1174-1180.	1.2	25
134	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	1.3	19
135	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016, 7, 44608-44620.	0.8	46
136	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	0.8	42
137	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , 2016, 1, e87607.	2.3	44
138	<i>PTEN</i> Methylation Dependent Sinonasal Mucosal Melanoma. <i>Cancer Research and Treatment</i> , 2016, 48, 853-858.	1.3	6
139	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016, 263, 96-102.	2.1	56
140	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 385.	1.1	46
141	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	1.1	124
142	Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. <i>Supportive Care in Cancer</i> , 2016, 24, 3379-3389.	1.0	14
143	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. <i>Journal of Surgical Oncology</i> , 2016, 114, 859-864.	0.8	13
144	Cranofacial osteosarcoma: Single institutional experience in <sc>K</sc>orea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e149-53.	0.7	11

#	ARTICLE	IF	CITATIONS
145	A novel <i>TP53-KPNA3</i> translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000992.	0.5	13
146	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059.	1.2	12
147	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. <i>Nature Communications</i> , 2016, 7, 12983.	5.8	123
148	Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. <i>Oncology</i> , 2016, 90, 248-254.	0.9	6
149	Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. <i>Supportive Care in Cancer</i> , 2016, 24, 4559-4566.	1.0	4
150	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	0.8	183
151	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 507-516.	0.6	11
152	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1002-1011.	0.3	51
153	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	6.3	610
154	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	1.2	16
155	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. <i>Gastric Cancer</i> , 2016, 19, 15-20.	2.7	51
156	Epstein-Barr virus BARP1-induced NF $\kappa$ B/miR-146a/SMAD4 alterations in stomach cancer cells. <i>Oncotarget</i> , 2016, 7, 82213-82227.	0.8	31
157	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. <i>Oncotarget</i> , 2016, 7, 72099-72112.	0.8	16
158	Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. <i>Oncotarget</i> , 2016, 7, 4632-4646.	0.8	22
159	Prognostic implications of <i>PIK3CA</i> amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016, 7, 24549-24558.	0.8	7
160	<i>p16</i> ; <i>KRAS</i> Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 208-215.	1.3	11
161	Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. <i>Cancer Research and Treatment</i> , 2016, 48, 1286-1292.	1.3	5
162	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 503-503.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Prevalence of human papillomavirus infection and <scp>RAS</scp> mutation in sporadic keratoacanthoma. <i>International Journal of Dermatology</i> , 2015, 54, e453-7.	0.5	2
164	Low concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. <i>Journal of Dermatology</i> , 2015, 42, 881-888.	0.6	9
165	Current Strategy of Chemotherapy for Bone Tumors. <i>The Journal of the Korean Orthopaedic Association</i> , 2015, 50, 438.	0.0	0
166	Pain Palliation in Patients with Bone Metastases Using Magnetic Resonance-Guided Focused Ultrasound with Conformal Bone System: A Preliminary Report. <i>Yonsei Medical Journal</i> , 2015, 56, 503.	0.9	36
167	Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. <i>Gynecologic Oncology</i> , 2015, 136, 212-217.	0.6	4
168	Upregulated, 7q21 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. <i>Cellular Signalling</i> , 2015, 27, 1075-1086.	1.7	10
169	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Cut</i> , 2015, 64, 1721-1731.	6.1	197
170	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3938-3945.	0.7	13
171	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91
172	Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients. <i>European Journal of Oncology Nursing</i> , 2015, 19, 174-181.	0.9	48
173	Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. <i>European Journal of Oncology Nursing</i> , 2015, 19, 376-382.	0.9	144
174	Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. <i>Oncology</i> , 2015, 88, 147-156.	0.9	15
175	PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 76-85.	0.9	27
176	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 397-408.	1.1	32
177	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	1.1	58
178	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1226-1232.	1.0	9
179	<i>PINCH</i> presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015, 136, 2273-2283.	2.3	11
180	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 224-231.	0.7	50

#	ARTICLE	IF	CITATIONS
181	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. Journal of Clinical Oncology, 2015, 33, 10565-10565.	0.8	6
182	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€™Final overall and subgroup results.. Journal of Clinical Oncology, 2015, 33, 4003-4003.	0.8	11
183	A serum microRNA biomarker panel for detection of gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4060-4060.	0.8	2
184	Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. Journal of Clinical Oncology, 2015, 33, 4554-4554.	0.8	5
185	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€™A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. Journal of Clinical Oncology, 2015, 33, 9-9.	0.8	7
186	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. Journal of Clinical Oncology, 2015, 33, 464-464.	0.8	1
187	Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World Journal of Gastroenterology, 2015, 21, 2711.	1.4	23
188	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. Cancer Research and Treatment, 2015, 47, 781-789.	1.3	10
189	Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. Intestinal Research, 2015, 13, 274.	1.0	3
190	Do all patients with HER2-positive gastric/GEJ cancer benefit from trastuzumab?. Journal of Clinical Oncology, 2015, 33, 185-185.	0.8	0
191	Retrospective analysis of chemotherapy for the patients with advanced bladder adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 399-399.	0.8	0
192	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15020-e15020.	0.8	0
193	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	0.8	0
194	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, 4558-4558.	0.8	0
195	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113.	0.8	0
196	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. American Journal of Cancer Research, 2015, 5, 72-86.	1.4	10
197	Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. Annals of Dermatology, 2014, 26, 485.	0.3	22
198	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemotherapy and Pharmacology, 2014, 74, 799-808.	1.1	7

#	ARTICLE	IF	CITATIONS
199	A Case of Gingival Candidiasis with Bone Destruction on Gastric Cancer Patient Receiving Cytotoxic Chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.2	2
200	Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2014, 67, 33-39.	1.0	14
201	Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , 2014, 46, 316-324.	0.3	22
202	The Effect of Disintegrinâ€“Metalloproteinase ADAM9 in Gastric Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3074-3085.	1.9	35
203	Tumor perfusionâ€“related parameter of diffusionâ€“weighted magnetic resonance imaging: Correlation with histological microvessel density. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1554-1558.	1.9	115
204	The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFRâ€“MEKâ€“ERK Signaling and Is Silenced in Carcinomas by CpG Methylation. <i>Molecular Cancer Research</i> , 2014, 12, 228-238.	1.5	58
205	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	0.8	355
206	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014, 12, 232.	0.8	30
207	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	0.9	382
208	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	0.9	9
209	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	0.9	25
210	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. <i>European Journal of Cancer</i> , 2014, 50, 746-752.	1.3	18
211	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
212	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	1.4	31
213	Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case. <i>Case Reports in Oncology</i> , 2014, 7, 337-342.	0.3	4
214	Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study. <i>Oncology</i> , 2014, 86, 329-335.	0.9	0
215	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4576-4576.	0.8	4
216	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 396-396.	0.8	9

#	ARTICLE	IF	CITATIONS
217	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 398-398.	0.8	7
218	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy.. Journal of Clinical Oncology, 2014, 32, 473-473.	0.8	1
219	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Korean Journal of Internal Medicine, 2014, 29, 246.	0.7	18
220	Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Cancer Research and Treatment, 2014, 46, 141-147.	1.3	16
221	A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 127-127.	0.8	0
222	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. Journal of Clinical Oncology, 2014, 32, e22164-e22164.	0.8	0
223	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. Journal of Clinical Oncology, 2014, 32, e15596-e15596.	0.8	0
224	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Supportive Care in Cancer, 2013, 21, 1751-1759.	1.0	38
225	Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Annals of Surgical Oncology, 2013, 20, 2615-2624.	0.7	18
226	Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. Radiotherapy and Oncology, 2013, 108, 72-77.	0.3	18
227	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	1.7	47
228	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Investigational New Drugs, 2013, 31, 1602-1608.	1.2	39
229	Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer, 2013, 13, 394.	1.1	35
230	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Investigational New Drugs, 2013, 31, 1-13.	1.2	11
231	Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program. Urology, 2013, 81, 143-149.	0.5	16
232	Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. Journal of General Virology, 2013, 94, 497-506.	1.3	47
233	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. Journal of Surgical Oncology, 2013, 107, 613-618.	0.8	20
234	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemotherapy and Pharmacology, 2013, 72, 825-835.	1.1	57

#	ARTICLE	IF	CITATIONS
235	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 853-860.	1.1	5
236	Difference of interferon- $\beta$ and interferon- $\gamma$ on melanoma growth and lymph node metastasis in mice. <i>Melanoma Research</i> , 2013, 23, 114-124.	0.6	20
237	Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 731-737.	0.8	154
238	Integrated epigenomics identifies <i>BMP4</i> as a modulator of cisplatin sensitivity in gastric cancer. <i>Gut</i> , 2013, 62, 22-33.	6.1	88
239	Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003.	0.6	27
240	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013, 54, 52-60.	0.8	11
241	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 265-272.	0.7	8
242	Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , 2013, 31, 1202-1208.	1.8	9
243	PIK3CA Mutations in Hepatocellular Carcinoma in Korea. <i>Yonsei Medical Journal</i> , 2013, 54, 883.	0.9	4
244	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 865.	0.9	18
245	Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung. <i>Yonsei Medical Journal</i> , 2013, 54, 854.	0.9	14
246	Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e15573-e15573.	0.8	0
247	Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. <i>Oncology Letters</i> , 2012, 3, 699-703.	0.8	11
248	A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 357-363.	0.6	5
249	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. <i>Gut</i> , 2012, 61, 673-684.	6.1	562
250	Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: Implications for postoperative radiotherapy. <i>Radiotherapy and Oncology</i> , 2012, 104, 367-373.	0.3	48
251	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	1.3	84
252	A randomized phase II trial of S-1-oxaliplatin versus capecitabine+oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012, 48, 518-526.	1.3	116

#	ARTICLE	IF	CITATIONS
253	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012, 13, 348.	1.2	114
254	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. <i>BMC Cancer</i> , 2012, 12, 322.	1.1	20
255	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012, 12, 471.	1.1	1
256	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. <i>Nature Genetics</i> , 2012, 44, 570-574.	9.4	560
257	EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI. <i>Yonsei Medical Journal</i> , 2012, 53, 1128.	0.9	23
258	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and Tj ETQq0 0 0 rgBT /Overlock 10 Tf) treated with chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 1501-1510.	1.2	18
259	Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2012, 92, 236-242.	0.9	32
260	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. <i>Cancer</i> , 2012, 118, 729-739.	2.0	132
261	Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 635-642.	1.1	22
262	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 357-363.	1.2	7
263	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 672-680.	1.2	20
264	Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4077-4077.	0.8	10
265	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	0.8	1
266	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. <i>PLoS ONE</i> , 2012, 7, e45127.	1.1	15
267	Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis. <i>Cancer Research and Treatment</i> , 2012, 44, 43-49.	1.3	14
268	Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. <i>Hepato-Gastroenterology</i> , 2012, 59, 1313-8.	0.5	4
269	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15064-e15064.	0.8	1
270	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4536-4536.	0.8	4



#	ARTICLE	IF	CITATIONS
271	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14652-e14652.	0.8	0
272	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 4538-4538.	0.8	0
273	The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14580-e14580.	0.8	0
274	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Journal of Clinical Oncology, 2011, 29, 3968-3976.	0.8	1,003
275	Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology, 2011, 141, 476-485.e11.	0.6	304
276	<i>CD44-SLC1A2</i> Gene Fusions in Gastric Cancer. Science Translational Medicine, 2011, 3, 77ra30.	5.8	54
277	Systematic Analyses of Genes Associated with Radiosensitizing Effect by Celecoxib, a Specific Cyclooxygenase-2 Inhibitor. Journal of Radiation Research, 2011, 52, 752-765.	0.8	6
278	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 801-810.	0.7	14
279	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncology Reports, 2011, 25, 717-27.	1.2	16
280	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Experimental and Therapeutic Medicine, 2011, 2, 685-693.	0.8	33
281	Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 258-269.	0.7	9
282	Prevalence and associated factors of psychological distress among Korean cancer patients. General Hospital Psychiatry, 2011, 33, 246-252.	1.2	37
283	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Research and Treatment, 2011, 125, 55-63.	1.1	48
284	Brain metastases from colorectal carcinoma: prognostic factors and outcome. Journal of Neuro-Oncology, 2011, 101, 49-55.	1.4	81
285	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 991-999.	1.1	4
286	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer, 2011, 117, 2050-2057.	2.0	42
287	A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. Oncology, 2011, 80, 142-150.	0.9	36
288	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology, 2011, 80, 395-405.	0.9	48

#	ARTICLE	IF	CITATIONS
289	Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. <i>Oncology</i> , 2011, 80, 107-117.	0.9	11
290	Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis. <i>Oncology</i> , 2011, 81, 175-183.	0.9	18
291	Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1344-1350.	0.6	14
292	A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. <i>PLoS Genetics</i> , 2011, 7, e1002415.	1.5	42
293	A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 56-60.	0.6	3
294	The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. <i>Annals of Surgical Oncology</i> , 2010, 17, 3259-3268.	0.7	43
295	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805.	1.1	23
296	Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 387-394.	1.2	41
297	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 517-526.	1.2	25
298	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1901-1913.	1.2	26
299	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010, 28, 650-658.	1.2	21
300	Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 201, 73-80.	1.0	24
301	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010, 101, 2200-2206.	1.7	22
302	Green Tea Consumption and Stomach Cancer Risk: A Meta-Analysis. <i>Epidemiology and Health</i> , 2010, 32, e2010001.	0.8	34
303	Kidney Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i51-i56.	0.6	49
304	Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. <i>International Journal of Hyperthermia</i> , 2010, 26, 305-315.	1.1	42
305	Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m <sup>2</sup> bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 29-35.	0.6	2
306	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010, 288, 124-132.	3.2	34

#	ARTICLE	IF	CITATIONS
307	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307.	0.3	26
308	Wernicke's Encephalopathy in Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2010, 42, 77.	1.3	16
309	Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis. <i>Cancer Research and Treatment</i> , 2010, 42, 180.	1.3	10
310	Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites. <i>Cancer Research and Treatment</i> , 2010, 42, 217.	1.3	29
311	Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. <i>International Journal of Oncology</i> , 2009, 34, 837-46.	1.4	2
312	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009, 34, 787-96.	1.4	1
313	Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction. <i>Yonsei Medical Journal</i> , 2009, 50, 296.	0.9	3
314	A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. <i>Oncology</i> , 2009, 77, 349-357.	0.9	6
315	Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. <i>PLoS Genetics</i> , 2009, 5, e1000676.	1.5	354
316	A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. <i>Journal of Bioscience and Bioengineering</i> , 2009, 108, 252-258.	1.1	7
317	The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 275-280.	0.8	52
318	Increments of $\alpha$ -dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 100, 459-465.	0.8	7
319	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 919-927.	1.1	6
320	Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 475-479.	1.4	25
321	Prediction of Recurrence of Early Gastric Cancer After Curative Resection. <i>Annals of Surgical Oncology</i> , 2009, 16, 1896-1902.	0.7	84
322	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. <i>Cancer Letters</i> , 2009, 277, 155-163.	3.2	13
323	Subtelomeric DNA methylation and telomere length in human cancer cells. <i>Cancer Letters</i> , 2009, 281, 82-91.	3.2	14
324	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. <i>Genomics</i> , 2009, 93, 52-61.	1.3	16

#	ARTICLE	IF	CITATIONS
325	Identification of significant regional genetic variations using continuous CNV values in aCGH data. <i>Genomics</i> , 2009, 94, 317-323.	1.3	3
326	Changes of Telomerase Activity by Alternative Splicing of Full-Length and $\hat{1}^2$ Variants of hTERT in Breast Cancer Patients. <i>Oncology Research</i> , 2009, 18, 213-220.	0.6	19
327	Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67.	1.3	63
328	Prognosis of pN3 Stage Gastric Cancer. <i>Cancer Research and Treatment</i> , 2009, 41, 73.	1.3	18
329	Clinical Value of Ezrin Expression in Primary Osteosarcoma. <i>Cancer Research and Treatment</i> , 2009, 41, 138.	1.3	39
330	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	1.3	25
331	Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status.. <i>Blood</i> , 2009, 114, 2637-2637.	0.6	0
332	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 241-250.	1.1	472
333	Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. <i>BMC Bioinformatics</i> , 2008, 9, 283.	1.2	14
334	SNPAnalyzer 2.0: A web-based integrated workbench for linkage disequilibrium analysis and association analysis. <i>BMC Bioinformatics</i> , 2008, 9, 290.	1.2	106
335	Variation of the 3 $\hat{e}^2$ telomeric overhang lengths in human cells. <i>Cancer Letters</i> , 2008, 264, 107-118.	3.2	10
336	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008, 270, 269-276.	3.2	6
337	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 361-366.	0.3	8
338	Angiogenic Factor Thymidine Phosphorylase Increases Cancer Cell Invasion Activity in Patients with Gastric Adenocarcinoma. <i>Molecular Cancer Research</i> , 2008, 6, 1554-1566.	1.5	27
339	Inhibition of Gastric Cancer Invasion and Metastasis by <i>PLA2G2A</i> , a Novel $\hat{1}^2$ -Catenin/TCF Target Gene. <i>Cancer Research</i> , 2008, 68, 4277-4286.	0.4	103
340	Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 1091.	2.3	22
341	OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation. <i>PLoS ONE</i> , 2008, 3, e2990.	1.1	92
342	S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer. <i>Korean Journal of Internal Medicine</i> , 2008, 23, 37.	0.7	0

#	ARTICLE	IF	CITATIONS
343	Multi-Institutional Phase II Study of S <sup>1</sup> Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. <i>Oncologist</i> , 2007, 12, 543-554.	1.9	33
344	An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients. <i>Oncologist</i> , 2007, 12, 622-630.	1.9	48
345	Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 487-492.	0.6	33
346	Role of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. <i>Oncology</i> , 2007, 72, 104-110.	0.9	101
347	Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , 2007, 89, 451-459.	1.3	54
348	Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 1033-1040.	1.8	38
349	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007, 46, 547-549.	0.8	1
350	Clinical Role of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia. <i>Yonsei Medical Journal</i> , 2007, 48, 171.	0.9	15
351	Whole genome analysis for liver metastasis gene signatures in colorectal cancer. <i>International Journal of Cancer</i> , 2007, 121, 2005-2012.	2.3	203
352	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , 2007, 95, 461-468.	0.8	89
353	A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 204-210.	0.4	60
354	Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , 2007, 8, 218.	1.2	10
355	Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. <i>BMC Genomics</i> , 2007, 8, 305.	1.2	30
356	Gastrointestinal Stromal Tumor of the Rectum: An Analysis of Seven Cases. <i>Surgery Today</i> , 2007, 37, 455-459.	0.7	30
357	Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. <i>Annals of Surgical Oncology</i> , 2007, 14, 2730-2737.	0.7	72
358	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81.	1.1	10
359	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 157-165.	1.1	13
360	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 315-321.	1.1	18

#	ARTICLE	IF	CITATIONS
361	Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 31-37.	1.1	2
362	An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions. <i>Cancer Research and Treatment</i> , 2007, 39, 74.	1.3	9
363	A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report. <i>Cancer Research and Treatment</i> , 2007, 39, 134.	1.3	4
364	Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. <i>Wiley Series in Probability and Statistics</i> , 2006, , 333-343.	0.0	1
365	Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 429-438.	0.7	52
366	Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. <i>Cancer Science</i> , 2006, 97, 1082-1092.	1.7	16
367	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 313-320.	1.1	8
368	A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. <i>Oncology</i> , 2006, 70, 63-70.	0.9	15
369	Intermediate Dose 5-Fluorouracil-Induced Encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 55-59.	0.6	53
370	Activation of Hypoxia-Inducible Factor-1 $\alpha$ Is Necessary for Lysophosphatidic Acid-Induced Vascular Endothelial Growth Factor Expression. <i>Clinical Cancer Research</i> , 2006, 12, 6351-6358.	3.2	85
371	Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports. <i>Cancer Research and Treatment</i> , 2006, 38, 184.	1.3	1
372	Systematic analysis of cDNA microarray-based CGH. <i>International Journal of Molecular Medicine</i> , 2006, 17, 261-7.	1.8	10
373	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 215-221.	1.1	63
374	Cyclic Induction of Senescence with Intermittent AZT Treatment Accelerates both Apoptosis and Telomere Loss. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 227-236.	1.1	30
375	Clinical Implication of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 1455-1455.	0.6	0
376	Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , 2005, 11, 79-86.	3.2	23
377	Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. <i>Clinical Cancer Research</i> , 2005, 11, 612-20.	3.2	31
378	Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. <i>International Journal of Molecular Medicine</i> , 2005, 16, 857-63.	1.8	5

#	ARTICLE	IF	CITATIONS
379	Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1857-1864.	0.6	15
380	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. <i>Cancer Letters</i> , 2004, 214, 215-224.	3.2	63
381	Increased Expression of Matrix Metalloproteinase 9 Correlates with Poor Prognostic Variables in Renal Cell Carcinoma. <i>European Urology</i> , 2003, 44, 560-566.	0.9	77
382	Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. <i>International Journal of Molecular Medicine</i> , 2002, 10, 251-6.	1.8	1
383	Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , 2000, 150, 137-145.	3.2	23
384	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 41-50.	1.1	15
385	An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1998, 39, 463.	0.9	3
386	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , 1998, 39, 27.	0.9	23
387	Relationship between p53 Overexpression and Gastric Cancer Progression. <i>Oncology</i> , 1997, 54, 166-170.	0.9	19
388	Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. <i>Cancer Letters</i> , 1997, 118, 37-46.	3.2	16
389	Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 175-181.	1.1	38
390	P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 65-72.	1.1	38
391	Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 484-489.	0.6	12
392	A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 569-572.	0.6	13
393	Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain. <i>Oncology</i> , 1996, 53, 192-197.	0.9	30
394	Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , 1996, 14, 512-519.	1.7	41
395	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 1970, 47, 9-17.	1.3	12